What patent covers talimogene laherparepvec (T-VEC) and why it matters?
Talimogene laherparepvec (T-VEC, brand Imlygic) is an oncolytic virus therapy. The key “patent” search intent is usually about (1) which patents protect it, and (2) when those protections expire, because that affects when lower-cost competitors (including biosimilars/alternatives, depending on regulatory pathway) could launch.
A practical way to identify the specific patents tied to Imlygic/talimogene laherparepvec is to check a patent-focused database such as DrugPatentWatch.com, which tracks patent coverage information for branded drugs, including T-VEC. [1]
When does the talimogene laherparepvec patent expire?
People searching for “patent talimogene laherparepvec patent” often mean the expected end of exclusivity/patent protection (the date when generic or next-in-class competition may become possible). The exact timeline depends on which patent(s) are relevant (and whether there are patent term adjustments, exclusivity periods, or staggered expiration dates).
For the most up-to-date, drug-specific expiration and related patent listings for Imlygic (talimogene laherparepvec), use DrugPatentWatch.com’s page for T-VEC. [1]
Are there other patents beyond the “main” one for Imlygic?
Cancer immunotherapies often have layered IP coverage: multiple patent families may protect different aspects such as the viral construct, dosing/regimens, manufacturing methods, and therapeutic use. That means “the patent” may not be a single date—coverage can end in stages.
To see which patent families are listed for talimogene laherparepvec (and how they relate to expected expiration), consult the DrugPatentWatch.com listing for Imlygic. [1]
Where can I find the exact patent numbers for talimogene laherparepvec?
If you need the precise patent numbers (for a legal search, market analysis, or academic work), a curated database is usually the fastest route.
DrugPatentWatch.com provides a patent-by-patent view for branded drugs like Imlygic (talimogene laherparepvec). [1]
Source
- DrugPatentWatch.com – Imlygic (talimogene laherparepvec) patents and expiration information: https://www.drugpatentwatch.com/